Agora: An openly available web resource to enable exploration of nascent therapeutic targets for Alzheimer’s disease
Jessica S Britton, Jesse C Wiley, Jaclyn Beck, Karina Leal, Lawrence Yi, Brad Macdonald, Khai Do, Stockard Simon, Hallie Swan, Nicholas Grosenbacher, Thomas Yu, Jay Hodgson, Anna GreenwoodAbstract
Background
Agora (
Method
Agora enables the sharing of information about potential AD therapeutic targets by surfacing data visualizations, summary evidence, and results from targeted validation studies. Agora users can browse a list of over 950 potential therapeutic targets that have been nominated by the NIA’s Accelerating Medicines Partnership in AD (AMP‐AD) consortium and Target Enablement to Accelerate Therapy Development for AD (TREAT‐AD) centers, and by the broader AD research community; see visualizations and summarized information based on harmonized genome‐wide analyses of high‐dimensional human transcriptomic, proteomic, and metabolomic data; use interactive tools designed to enable non‐bioinformaticians to evaluate and compare complex multi‐omic data; and access the underlying data that drives the results and visualizations presented in the application.
Result
Agora presents information and results about AD targets using approaches that make this information accessible to a broad spectrum of AD researchers. Recent updates to Agora include 1) comparative and per‐target visualizations for SRM proteomic differential expression results and 2) enabling the discovery of TREAT‐AD Target Experimental Resources for supported targets.
Conclusion
The advancement of promising new AD therapeutics requires efforts from research groups and specialties across both academia and industry. Agora enables the AD research community to develop and share target hypotheses that will accelerate the investigation of promising new AD therapeutic targets, pathways and mechanisms.